✦ LIBER ✦

A Phase I/II Randomized Open-Label Multicenter Trial of Efalizumab, a Humanized Anti-CD11a, Anti-LFA-1 in Renal Transplantation

✍ Scribed by F. Vincenti; R. Mendez; M. Pescovitz; P. R. Rajagopalan; A. H. Wilkinson; K. Butt; D. Laskow; D. P. Slakey; M. I. Lorber; J. P. Garg; M. Garovoy

Book ID: 114804417
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 82 KB
Volume: 7
Category: Article
ISSN: 1600-6135
DOI: 10.1111/j.1600-6143.2007.01845.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recombinant human anti–transforming grow

Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192

✍ Christopher P. Denton; Peter A. Merkel; Daniel E. Furst; Dinesh Khanna; Paul Eme 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 1 views

## Abstract ## Objective To evaluate CAT‐192, a recombinant human antibody that neutralizes transforming growth factor β1 (TGFβ1), in the treatment of early‐stage diffuse cutaneous systemic sclerosis (dcSSc). ## Methods Patients with SSc duration of <18 months were randomly assigned to the place

Prospective randomized open-label multic

Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis

✍ Daniel C. Baumgart; Stephan R. Targan; Axel U. Dignass; Lloyd Mayer; Gert van As 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB

## Background: Visilizumab is a humanized igg(2) monoclonal anti-cd3 antibody. we evaluated its safety and dose response in severe intravenous steroid-refractory ulcerative colitis (uc). ## Methods: In all, 104 patients were treated. in stage i, 73 patients were randomly assigned to receive intra

Ocrelizumab, a humanized anti-CD20 monoc

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study

✍ Mark C. Genovese; Jeffrey L. Kaine; Mitchell B. Lowenstein; José Del Giudice; An 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 623 KB

A phase II randomized open-label study a

A phase II randomized open-label study anti-CMV hyperimmune globulin vs standard IGIV for prevention of cytomegalovirus (CMV) reactivation in hypogammaglobulinemic adult allogeneic hematopoietic stem cell transplants (AHSCT)

✍ J.S. Bubalo; J.F. Leis; P.T. Curtin; A. Simic; N. Subbiah; C. Fowler; A. Dunn; B 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Targeted radiotherapy in the conditionin

Targeted radiotherapy in the conditioning prior to haematopoietic stem cell transplantation: Results of a phase I trial using an yttrium-90-labelled anti-CD66 murine monoclonal antibody demonstrating consistently high BM uptake

✍ K.H. Orchard; M. Cooper; V. Lewington; M. Tristam; M. Zivanovic; J. Thom; S. Qua 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 79 KB

A phase I/randomized phase II, non-compa

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

✍ Roger B. Cohen; Corey J. Langer; George Rajan Simon; Peter David Eisenberg; John 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 387 KB